Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Thyroid Neoplasms 11Adenocarcinoma, Follicular 5Thyroid Cancer, Papillary 4Xerostomia 2Thyroid Diseases 1Sialadenitis 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Infertility 1Hyperthyroidism 1Head and Neck Neoplasms 1

Interventions

3-Iodobenzylguanidine 5Doxorubicin 3cabozantinib 2Temozolomide 2Radiotherapy 2Phenoxybenzamine 2Ifosfamide 2Filgrastim 2Everolimus 2Doxazosin 2Dexmedetomidine 2vatalanib 1temsirolimus 1pegfilgrastim 1lenvatinib 1fostamatinib 1atezolizumab 1anlotinib 1Vinorelbine 1Tamoxifen 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Saline Solution 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pheochromocytoma × Iodine-131 × Clear all
NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡